GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Price-to-Tangible-Book

KYTX (Kyverna Therapeutics) Price-to-Tangible-Book : 0.72 (As of Sep. 25, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Price-to-Tangible-Book?

As of today (2024-09-25), Kyverna Therapeutics's share price is $5.58. Kyverna Therapeutics's Tangible Book per Share of Jun. 2024 for the quarter that ended in Jun. 2024 was $7.73. Hence, Kyverna Therapeutics's Price to Tangible Book Ratio of today is 0.72.

The historical rank and industry rank for Kyverna Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

KYTX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.72   Med: 1.97   Max: 2.97
Current: 0.72

During the past 3 years, Kyverna Therapeutics's highest Price to Tangible Book Ratio was 2.97. The lowest was 0.72. And the median was 1.97.

KYTX's Price-to-Tangible-Book is ranked better than
87.99% of 1199 companies
in the Biotechnology industry
Industry Median: 2.73 vs KYTX: 0.72

A closely related ratio is called PB Ratio. As of today, Kyverna Therapeutics's share price is $5.58. Kyverna Therapeutics's Book Value per Sharefor the quarter that ended in Jun. 2024 was $7.73. Hence, Kyverna Therapeutics's P/B Ratio of today is 0.72.


Kyverna Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Kyverna Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Price-to-Tangible-Book Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Price-to-Tangible-Book
- - -

Kyverna Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only - - - 2.97 0.97

Competitive Comparison of Kyverna Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Kyverna Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyverna Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kyverna Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Kyverna Therapeutics's Price-to-Tangible-Book falls into.



Kyverna Therapeutics Price-to-Tangible-Book Calculation

Kyverna Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Jun. 2024 )
=5.58/7.73
=0.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Kyverna Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyverna Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
5980 Horton Street, STE 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics Headlines